Loading
Valbiotis Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 02 Jul 2025.
Valbiotis: what insiders have been doing
Every trade that managers of Valbiotis disclose to AMF is tracked on this page. The company sits in the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for Valbiotis. The previous disclosure was published on 2 July 2025.
Over the whole record (from 2021), the tally stands at 3 purchases and no sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from AMF. Past trades are no guide to future returns.
Insider Decl.
9
Thresholds
n/a
Buy Volume
€157,085
3 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleSébastien Peltier2 buys
Pascal Sirvent1 buy
Since the insiders bought
- -4.9%Entry €0.86 · Close at T+365 €0.82
- +2.3%Entry €0.78 · Close at T+365 €0.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
as of FY 2025FY ended December 2025 · cache
€0.60
Analyst consensus
2 analysts1.00/5
€1.80Target €1.85(+207%)€1.90
Income statement
Revenue€905k
Gross profit-€1.3M-146% margin
EBITDA-€9.0M-990% margin
Net income-€9.4M-1040.6% margin
Valuation
PER (forward)-7.5x
P/Book2.0x
Beta-0.14
Balance sheet & cash
Market cap€21.4M
Total debt€5.1M
Free Cash Flow-€8.2M
Debt / Equity73%
Profitability & ownership
ROE-108.7%
ROA-34.9%
% insiders2.6%
% institutions1.5%
Last declaration on 2 July 2025
Declarations9 total
113,636 shares@ €0.8870.2% of flowActionEuronext Growth ParisISIN FR00132548512025DD1045570
Canonical exit: 28 Sept 2025 (T+90)
39,248 shares@ €1.0829.8% of flowActionEuronext Growth ParisISIN FR00132548512025DD1045550
Canonical exit: 9 Jul 2025 (T+90)
18,000 shares@ €0.816532.2% of flowActionEuronext Growth ParisISIN FR00132548512025DD1044710
Canonical exit: 23 Sept 2025 (T+90)
10,400 shares@ €4.43100.0% of flowActionHors plateforme de négociationISIN FR00132548512023DD887711
2,095 shares@ €2.581.7% of flowActionEuronext Growth ParisISIN FR00132548512022DD817635
42,480 shares@ €6.5985.9% of flowActionEuronext Growth ParisISIN FR00132548512022DD817632
10,000 shares@ €4.0412.4% of flowBSPCEEuronext Growth ParisISIN FR00132548512021DD765291
2,000 shares@ €2.5811.3% of flowBSPCEEuronext Growth ParisISIN FR00132548512021DD763258
10,000 shares@ €2.5856.5% of flowBSPCEEuronext Growth ParisISIN FR00132548512021DD763256
9 of 9 declarations
About Valbiotis
Valbiotis is a French health company focused on the development and commercialization of scientifically tested dietary supplements designed to support health throughout life. Listed on Euronext Growth Paris under the ticker ALVAL and ISIN FR0013254851, the company was founded in La Rochelle in 2014 by Sébastien Peltier and co-founders. Its original business model was built around research in nutritional health and metabolic prevention. After joining Euronext Growth in 2017, Valbiotis spent several years building a proprietary R&D platform before pivoting toward a more commercial model in 2024-2025.
Today, the company’s business is organized around two main product families: Valbiotis PRO® and Valbiotis PLUS®. The Valbiotis PRO® range is supported by ten years of research and proprietary clinical studies, with a focus on scientifically backed solutions for cardio-metabolic health concerns such as metabolism, glucose control, lipids, blood pressure, and weight management. The Valbiotis PLUS® range addresses key peripheral factors involved in cardio-metabolic balance and relies on ingredients whose efficacy and safety are widely supported by scientific literature. In 2025, Valbiotis expanded its portfolio and accelerated its commercial rollout, particularly through pharmacies, while increasing brand visibility among healthcare professionals and consumers.
Read moreShow less
From a market standpoint, Valbiotis occupies a niche position within the scientifically oriented dietary supplement segment, sitting between mass-market consumer wellness brands and more specialized health-oriented offerings. Its differentiation comes from clinical credibility, the quality of its formulations, and a preventive-health narrative anchored in science. The company reached an important milestone in 2024 with its first market launches, confirming its transition from a pure R&D story into a revenue-generating commercial health business.
Geographically, France remains Valbiotis’ core market and operational anchor. That said, the company has already begun international expansion, signing major partnerships in Asia and later in the Middle East, which indicates a targeted growth strategy beyond its domestic base. Recent notable events include a capital increase in June 2025 to support commercial expansion and, in autumn 2025, a reaffirmed roadmap extending through 2030. Valbiotis is also recognized as an innovative company and is part of Bpifrance’s Excellence network, reinforcing its profile as a science-driven health company with growth ambitions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
